Correction to: Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study

Satoshi Imaizumi^{1,2} · Yuhei Shiga¹ · Masahiro Ogawa¹ · Hideto Sako¹ · Yoshihisa Nagata¹ · Akira Matsunaga³ · Tetsuro Shirotani⁴ · Fumihiro Hoshino⁵ · Eiji Yahiro⁶ · Yuko Uehara⁷ · Natsumi Morito¹ · Hiroyuki Tanigawa⁸ · Dai Shimono⁹ · Mikio Fukushima¹⁰ · Hidekazu Sugihara¹¹ · Kenji Norimatsu¹² · Takaaki Kusumoto¹² · Keiji Saku^{1,13} · Shin-ichiro Miura^{1,13} · ACADEMIE Study Investigators

Published online: 10 April 2019
© Springer Japan KK, part of Springer Nature 2019

Correction to: Heart and Vessels
<https://doi.org/10.1007/s00380-018-1286-2>

In the Original publication of the article, the legend appearing inside the flow chart has been incorrectly published. The correct figure is provided below:

The updated Fig. 2 is given below,

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations''

The original article can be found online at <https://doi.org/10.1007/s00380-018-1286-2>.

✉ Shin-ichiro Miura
miuras@cis.fukuoka-u.ac.jp

- ¹ Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan
- ² Clinical Research and Ethics Center, Fukuoka University School of Medicine, Fukuoka, Japan
- ³ Department of Laboratory Medicine, Fukuoka University School of Medicine, Fukuoka, Japan
- ⁴ Shirotani Hospital, Fukuoka, Japan
- ⁵ Murakami Karindoh Hospital, Fukuoka, Japan
- ⁶ Fukuoka University Medical Education Center, Fukuoka University School of Medicine, Fukuoka, Japan

- ⁷ Showa Hospital, Fukuoka, Japan
- ⁸ Tanigawa Hospital, Nagasaki, Japan
- ⁹ Futata Tetsuhiro Clinic, Fukuoka, Japan
- ¹⁰ Fukushima Hospital, Oita, Japan
- ¹¹ Fukuseikai Hospital, Fukuoka, Japan
- ¹² Izumi General Medical Center, Kagoshima, Japan
- ¹³ Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine, Fukuoka, Japan

Fig. 2 Eligibility, randomization, and follow-up. *Systolic BP < 130 mmHg and diastolic BP < 80 mmHg in an office setting